Topoisomerase I/II inhibitor 2

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Topoisomerase I/II inhibitor 2 

Topoisomerase I/II inhibitor 2 (compound 1a) 是一种有效的拓扑异构酶 (Topoisomerase) 抑制剂,Huh7 与 LM9 细胞中的 IC50 分别为 9.82 μM 和 6.83 μM。Topoisomerase I/II inhibitor 2 对 DNA 拓扑异构酶 I/II 具有双重抑制,也能抑制小鼠模型中的异种移植肿瘤。Topoisomerase I/II inhibitor 2 具有治疗肝癌的潜在价值。

Topoisomerase I/II inhibitor 2

Topoisomerase I/II inhibitor 2 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Topoisomerase I/II inhibitor 2 (compound 1a) is a potent Topoisomerase inhibitor (IC50= 9.82 μM on Huh7 cells and 6.83 μM on LM9 cells). Topoisomerase I/II inhibitor 2 has dual inhibition on DNA topoisomerase I/II, also can obviously reduce the growth of xenograft tumor in mice model. Topoisomerase I/II inhibitor 2 has the potential value in treating liver cancer[1].

IC50 & Target

Topoisomerase I

 

Topoisomerase II

 

体外研究
(In Vitro)

Topoisomerase I/II inhibitor 2 (compound 1a) (0-150 μM; 72 hours) has favourable anti-proliferative activity in cancer cell lines, and better inhibitory activity on two human hepatocellular carcinoma cell lines (HuH7, LM9)[1].
Topoisomerase I/II inhibitor 2 (20 μM; 24 hours) has no damage to the DNA of HuH7 cells while some damage is noticed on LM9 cells[1].
Topoisomerase I/II inhibitor 2 (1.25-8 μM; 1-2 weeks) inhibits cell proliferation of LM9 and Huh7 in a concentration-dependent manner[1].
Topoisomerase I/II inhibitor 2 (1.25-8 μM; 24 hours) has a good inhibitory effect on the migration and invasion of LM9 and HuH7 cells with concentration-dependent manner[1].
Topoisomerase I/II inhibitor 2 (0-20 μM; 24 hours) can inhibit the expression of matrix metalloproteinases-9 (MMP-9) in LM9 and HuH7 cells[1].
Topoisomerase I/II inhibitor 2 (0-20 μM; 48 hours) inhibits cells proliferation by blocking cell cycle at the G2/M phase[1].
Topoisomerase I/II inhibitor 2 (3.5-20 μM; 48 hours) can injure mitochondrial function and induce cell apoptosis in a concentration-dependent manner[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line: LM9, HuH7, SK-hep-1, HepG2, HT-29, HCT-116, RKO, SW480, MCF-7, MDA-B-231, HGC-27, SGC-7901, BGC-823, A549, U251, HL-60, LO2[1]
Concentration: 0-150 μM
Incubation Time: 72 hours
Result: Displayed favourable anti-proliferative activity and had better inhibitory activity on two human hepatocellular carcinoma cell lines (HuH7, LM9).

Western Blot Analysis

Cell Line: LM9 and HuH7 cells[1]
Concentration: 0, 3.75, 7.5, 15 μM in LM9; 0, 5, 10, 20 μM in HuH7
Incubation Time: 48 hours
Result: Inhibited the expression of MMP-9.

Cell Cycle Analysis

Cell Line: LM9 and HuH7 cells[1]
Concentration: 0, 3.75, 7.5, 15 μM in LM9; 0, 5, 10, 20 μM in HuH7
Incubation Time: 48 hours
Result: Inhibited cells proliferation by blocking cell cycle at the G2/M phase.

Apoptosis Analysis

Cell Line: LM9 and HuH7 cells[1]
Concentration: 3.5, 7, 14 μM in LM9; 5, 10, 20 μM in HuH7
Incubation Time: 48 hours
Result: Induced apoptosis in a dose-dependent manner.

分子量

336.34

Formula

C19H16N2O4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Deng X, et al. Design, synthesis and anti-hepatocellular carcinoma activity of 3-arylisoquinoline alkaloids. Eur J Med Chem. 2022;228:113985.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务